CVD Equipment Corporation (NASDAQ:CVV)
CVD Equipment is winding down manufacturing, cutting half its staff and weighing liquidation, with $23.5 million of cash and a 130,000-square-foot Long Island property central to…
CVD Equipment is winding down manufacturing, cutting half its staff and weighing liquidation, with $23.5 million of cash and a 130,000-square-foot Long Island property central to…
$TLYS turnaround looking good: ° Same-store comps +12.1% ° August (first month of Q3) comps +14.6% ° 13 month steak of growth ° Cash + securities $62.2M vs $50.7M ° Q2 net income $8.4M up from $3.2M Gross margin +300 bps Most important, earings I bought my daughter on Tilly's store visit are her fav pair, so wins all around 🥳
$NTSK absolutely smash print NNARR bounced to $54M + rev growth re-accelerated steller
This $APTV underperformance is interesting. 🤨 https://t.co/DHfLEh6lkf
$GPRO - Currently zero short borrow at IBKR. Squeezing the shorts.
$GPRO Squeezing here to $1.7/share. Up from $1.3 earlier today. I suspect the M&A caused alot of short sellers to enter the market and the borrow situation could get crazy, similar to $BYND or $BIRD. https://t.co/YgNwMHMLAF
*THOMA BRAVO'S PROOFPOINT IS SAID IN TALKS TO ACQUIRE VARONIS $VRNS https://t.co/dQEBQsKgGl
@HiddenGemsInves $CHCI ° Asset light, high ROIC asset manager ° Track record of revenue, FCF growth, clear strategy ° ~30% owned by Dwight Shar, founder/former CEO of $NVR ° move into data center development is a potential grand slam - a cheap call option
Nintendo expects software, digital sales and character licensing to drive growth, with FY2027 revenue forecast at ¥2.05 trillion and…
Lululemon’s North American sales, margins and legging demand are falling as Alo and Vuori gain share, leaving its brand moat and depressed…
Lululemon’s growth stalled as affordable-luxury apparel brands face fading post-Covid demand, cheap social-media influence and China…
Apollo Global Management’s five defining deals, from Executive Life to Intel, built a $1 trillion asset manager spanning insurance and…
TSOH weekly roundup covers Meta’s child-safety settlement, Markel’s leadership transition, Peloton’s gym strategy and an upcoming Alarm.com…
NET Power’s $1.80 shares are paired with January $2 covered calls for 40 cents as the company pivots from carbon capture to Permian…
Tsakos Energy Navigation benefits from higher oil prices and stronger tanker sentiment, but faces long-term demand destruction and…
Joby Aviation is initiated at Accumulate after booking $116m of trailing revenue, forming a Toyota manufacturing venture and agreeing to…
NewtekOne’s bank conversion and retention of SBA-guaranteed loans target recurring income, while a 6% yield and book-value valuation…
Sofwave Medical grew Q2 revenue 43% as recurring usage fees reached 46% of sales for its non-invasive ultrasound skin-tightening devices.
HNRG · long Hallador Energy, a coal producer, is pitched as a long based on five value components and potential 2026 catalysts.
Priority Technology’s chairman offered $6.00 to $6.15 a share to take PRTH private, while Zack Buckley argues Treasury Solutions and…
Imperial Petroleum's record Q2 cash generation, major share repurchases and a $32 million Suezmax sale gain set up another record quarter.
Amplitude reported Q2 revenue of $100.9 million, up 21%, as agentic AI and LLM vendors challenge the moat of its product analytics software.
Kosmos Energy (KOS) is pitched as an oil stock poised to outperform if oil stays above $70-$80, supported by a claimed 2 billion-barrel…
BridgeBio Pharma raised Attruby peak-sales guidance as kidney-benefit data, fewer hospital days and competitor setbacks strengthen its…
TransDigm’s sole-source aerospace parts generate roughly 70% aftermarket margins, with 90% of revenue tied to owned IP and 80% from…
Deckers Outdoor has fallen about 60% from its late-2024 peak and trades at 11x earnings as HOKA growth slows.
Union Pacific’s $85 billion Norfolk Southern merger pitch centers on a coast-to-coast rail network that cuts interchange delays and wins…
Dyne Therapeutics fell 16% after Novartis’ HARBOR failure raised doubts that RNA-targeting biomarker gains translate into functional…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.